✦ LIBER ✦

CELL BIOLOGY:How a Growth Control Path Takes a Wrong Turn to Cancer

✍ Scribed by Pennisi, E.

Book ID: 121159942
Publisher: American Association for the Advancement of Science
Year: 1998
Tongue: English
Weight: 1018 KB
Volume: 281
Category: Article
ISSN: 0036-8075
DOI: 10.1126/science.281.5382.1438

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

p38 MAPK turns hepatocyte growth factor

p38 MAPK turns hepatocyte growth factor to a death signal that commits ovarian cancer cells to chemotherapy-induced apoptosis

✍ Nadia Coltella; Andrea Rasola; Elisa Nano; Chiara Bardella; Michela Fassetta; Ni 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 805 KB

## Abstract We recently showed that Hepatocyte Growth Factor (HGF), known as a survival factor, unexpectedly enhances apoptosis in human ovarian cancer cells treated with the front‐line chemotherapeutics cisplatin (CDDP) and paclitaxel (PTX). Here we demonstrate that this effect depends on the p38

Epidermal growth factor receptor immunoh

Epidermal growth factor receptor immunohistochemistry : Comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer

✍ Fred R. Hirsch; Rafal Dziadziuszko; Nick Thatcher; Helen Mann; Claire Watkins; D 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 2 views

## Abstract ## BACKGROUND The ISEL (Iressa Survival Evaluation in Lung Cancer) clinical trial evaluated the efficacy of gefitinib versus placebo in pretreated nonsmall‐cell lung cancer patients. Two different antibodies, scoring systems, and cutoff points of epidermal growth factor receptor (EGFR)